Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) – Equities researchers at Zacks Research reduced their Q1 2024 EPS estimates for shares of Teva Pharmaceutical Industries in a research note issued on Tuesday, September 5th. Zacks Research analyst K. Shah now forecasts that the company will post earnings of $0.48 per share for the quarter, down from their previous forecast of $0.49. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.16 per share.
A number of other research firms have also recently weighed in on TEVA. Morgan Stanley started coverage on shares of Teva Pharmaceutical Industries in a report on Thursday, May 25th. They set an “equal weight” rating and a $10.00 price objective on the stock. Evercore ISI raised shares of Teva Pharmaceutical Industries from an “in-line” rating to an “outperform” rating in a report on Thursday, May 18th. StockNews.com started coverage on Teva Pharmaceutical Industries in a report on Thursday, August 17th. They set a “buy” rating on the stock. Finally, UBS Group raised Teva Pharmaceutical Industries from a “sell” rating to a “neutral” rating and raised their price objective for the stock from $7.00 to $8.00 in a report on Thursday, July 6th. Two analysts have rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, Teva Pharmaceutical Industries has an average rating of “Hold” and an average price target of $10.14.
Teva Pharmaceutical Industries Stock Down 0.8 %
Shares of NYSE TEVA opened at $9.48 on Wednesday. The company has a market capitalization of $10.62 billion, a price-to-earnings ratio of -4.74, a price-to-earnings-growth ratio of 1.61 and a beta of 1.17. The company has a debt-to-equity ratio of 2.43, a current ratio of 1.02 and a quick ratio of 0.67. The business has a 50-day moving average of $8.91 and a two-hundred day moving average of $8.64. Teva Pharmaceutical Industries has a 1 year low of $7.09 and a 1 year high of $11.44.
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last posted its quarterly earnings results on Wednesday, August 2nd. The company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.52 by $0.02. The company had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.69 billion. Teva Pharmaceutical Industries had a negative net margin of 14.87% and a positive return on equity of 27.93%.
Insider Activity
In other news, insider Eric A. Hughes sold 52,742 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $8.30, for a total value of $437,758.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $8.30, for a total value of $437,758.60. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Eliyahu Sharon Kalif sold 35,125 shares of Teva Pharmaceutical Industries stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $9.73, for a total transaction of $341,766.25. Following the completion of the sale, the chief financial officer now directly owns 99,162 shares in the company, valued at approximately $964,846.26. The disclosure for this sale can be found here. Over the last three months, insiders sold 89,848 shares of company stock valued at $799,176. Insiders own 0.62% of the company’s stock.
Institutional Trading of Teva Pharmaceutical Industries
A number of institutional investors have recently added to or reduced their stakes in TEVA. Two Sigma Investments LP raised its holdings in Teva Pharmaceutical Industries by 5.3% during the fourth quarter. Two Sigma Investments LP now owns 5,561,666 shares of the company’s stock worth $50,722,000 after purchasing an additional 278,165 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Teva Pharmaceutical Industries by 4.8% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 377,326 shares of the company’s stock valued at $3,339,000 after acquiring an additional 17,151 shares in the last quarter. Nomura Asset Management Co. Ltd. increased its holdings in Teva Pharmaceutical Industries by 4.1% during the 1st quarter. Nomura Asset Management Co. Ltd. now owns 344,508 shares of the company’s stock valued at $3,049,000 after acquiring an additional 13,633 shares in the last quarter. Altshuler Shaham Ltd raised its position in Teva Pharmaceutical Industries by 295.7% during the first quarter. Altshuler Shaham Ltd now owns 316,382 shares of the company’s stock worth $2,798,000 after acquiring an additional 236,432 shares during the last quarter. Finally, MQS Management LLC acquired a new position in Teva Pharmaceutical Industries during the first quarter worth about $188,000. Hedge funds and other institutional investors own 43.23% of the company’s stock.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.
Read More
- Five stocks we like better than Teva Pharmaceutical Industries
- What is ChatGPT Stock? How to Invest in It
- These Quality Dividend Kings Grow their Dividends the Fastest
- How to Calculate Stock Profit
- 3 Growth Stocks to Buy in September
- 3 Tickers Leading a Meme Stock Revival
- 3 Underappreciated Stocks with Nowhere to Go But Up
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.
